Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Genmab
Biotech
Endometrial cancer data on Genmab’s Elahere rival beat forecast
The biotech reported a 50% unconfirmed response rate, beating the expectations of analysts to boost confidence ahead of a move into phase 3.
Nick Paul Taylor
May 23, 2025 9:22am
AbbVie alleges Genmab 'willfully blind' to trade secret theft
Mar 24, 2025 5:51am
Genmab axes anti-CD38 antibody after losing J&J support
Mar 10, 2025 2:13pm
Genmab buys 2nd antibody from Scancell in deal worth up to $630M
Dec 4, 2024 11:55am
Genmab open to more M&A if it makes 'strategic sense,’ CFO says
Nov 21, 2024 1:05pm
NJ biopharmas make pledge to give time off for clinical trials
Nov 20, 2024 10:00am
